{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:42Z","timestamp":1793924502949,"version":"4.8.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ajem.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T17:34:53Z","timestamp":1712424893000},"page":"16-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.1016","volume":"81","author":[{"given":"Christiaan","family":"van Nispen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Koyfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.burns.2015.03.012","article-title":"Complications of Stevens-Johnson syndrome beyond the eye and skin","volume":"42","author":"Saeed","year":"2016","journal-title":"Burns"},{"key":"10.1016\/j.ajem.2024.04.001_bb0010","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Res"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.mcna.2021.04.001","article-title":"Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis)","volume":"105","author":"Owen","year":"2021","journal-title":"Med Clin North Am"},{"issue":"7","key":"10.1016\/j.ajem.2024.04.001_bb0020","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","article-title":"Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"38","author":"Noe","year":"2020","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcpt.12660","article-title":"Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"43","author":"Wu","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.001_bb0045","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0050","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0055","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/bjd.13989","article-title":"Epidermal necrolysis: 60 years of errors and advances","volume":"173","author":"Heng","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.ajem.2024.04.001_bb0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"600","key":"10.1016\/j.ajem.2024.04.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/ACI.0000000000000914","article-title":"New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"23","author":"Saito","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.ajem.2024.04.001_bb0080","first-page":"267","article-title":"Stevens\u2013Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions","author":"Zimmerman","year":"2019","journal-title":"Oncol Crit Care"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0085","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10106","key":"10.1016\/j.ajem.2024.04.001_bb0090","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0100","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200001060-00003","article-title":"Drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"1","author":"Fritsch","year":"2000","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamadermatol.2014.4844","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission","volume":"151","author":"Bequignon","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2010.04.026","article-title":"Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN","volume":"150","author":"Morales","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2015.05.002","article-title":"Japanese research committee on severe cutaneous adverse reaction. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"160","author":"Sotozono","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archdermatol.2009.540","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijstd.IJSTD_61_19","article-title":"Study of genital manifestations of Stevens Johnson syndrome\/toxic epidermal necrolysis","volume":"43","author":"Gulanikar","year":"2022","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CCM.0b013e31829eb94f","article-title":"Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation","volume":"42","author":"de Prost","year":"2014","journal-title":"Crit Care Med"},{"issue":"19","key":"10.1016\/j.ajem.2024.04.001_bb0145","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"issue":"6 Pt 1","key":"10.1016\/j.ajem.2024.04.001_bb0150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clindermatol.2018.12.008","article-title":"The rash that presents as target lesions","volume":"37","author":"Wolf","year":"2019","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0160","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of dermatology hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ACI.0000000000000546","article-title":"Making a diagnosis in severe cutaneous drug hypersensitivity reactions","volume":"19","author":"Ardern-Jones","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0170","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ijd.15888","article-title":"Managing respiratory complications in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"61","author":"Lee","year":"2022","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40812-3","article-title":"Correlations between histopathologic findings, serum biomarker levels, and clinical outcomes in Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)","volume":"13","author":"Chuenwipasakul","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.burns.2019.09.006","article-title":"Upper airway involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"46","author":"Bhullar","year":"2020","journal-title":"Burns"},{"key":"10.1016\/j.ajem.2024.04.001_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0190","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jaad.2019.05.096","article-title":"Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients","volume":"81","author":"Koh","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0195","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0200","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40257-021-00661-0","article-title":"Culprit medications and risk factors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: population-based nested case-control study","volume":"23","author":"Gronich","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0205","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/j.ajem.2024.04.001_bb0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/dtb.2023.000041","article-title":"Antibiotic-associated Stevens-Johnson syndrome","volume":"61","year":"2023","journal-title":"Drug Ther Bull"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.001_bb0225","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajem.2024.04.001_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0235","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1590\/1806-9282.62.05.468","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review","volume":"62","author":"Wong","year":"2016","journal-title":"Rev Assoc Med Bras"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0240","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.det.2011.03.004","article-title":"Diagnosis and clinical features of pemphigus vulgaris","volume":"29","author":"Venugopal","year":"2011","journal-title":"Dermatol Clin"},{"issue":"7","key":"10.1016\/j.ajem.2024.04.001_bb0245","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/ced.14041","article-title":"Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management","volume":"44","author":"Melchionda","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0250","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/RHU.0000000000000830","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like lupus erythematosus","volume":"25","author":"Tankunakorn","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0255","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0738-081X(00)00185-1","article-title":"Linear IgA bullous dermatosis","volume":"19","author":"Guide","year":"2001","journal-title":"Clin Dermatol"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.001_bb0260","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/medicina57111157","article-title":"Staphylococcal scalded skin syndrome and bullous impetigo","volume":"57","author":"Brazel","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0265","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of graft-versus-host disease","volume":"37","author":"Ramachandran","year":"2019","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0270","first-page":"82","article-title":"Erythema multiforme: recognition and management","volume":"100","author":"Trayes","year":"2019","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0275","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.clindermatol.2020.06.008","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"38","author":"Cardones","year":"2020","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0280","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000529218","article-title":"Acute generalized exanthematous pustulosis: clinical characteristics, pathogenesis, and management","volume":"239","author":"Stadler","year":"2023","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0285","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clindermatol.2021.12.008","article-title":"Annular drug eruptions","volume":"40","author":"Wu","year":"2022","journal-title":"Clin Dermatol"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.001_bb0290","doi-asserted-by":"crossref","first-page":"724","DOI":"10.14423\/SMJ.0000000000000195","article-title":"Fixed drug eruptions: presentation, diagnosis, and management","volume":"107","author":"Flowers","year":"2014","journal-title":"South Med J"},{"key":"10.1016\/j.ajem.2024.04.001_bb0295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1874285801610010150","article-title":"A systemic review on staphylococcal scalded skin syndrome (SSSS): a rare and critical disease of neonates","volume":"10","author":"Mishra","year":"2016","journal-title":"Open Microbiol J"},{"key":"10.1016\/j.ajem.2024.04.001_bb0300","first-page":"243","article-title":"Sign of Nikolsky and related signs","volume":"69","author":"Sachdev","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0305","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4103\/jfmpc.jfmpc_889_19","article-title":"Nikolsky\u2019s sign: a pathognomic boon","volume":"9","author":"Maity","year":"2020","journal-title":"J Family Med Prim Care"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0310","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI69071","article-title":"Desmoglein-1, differentiation, and disease","volume":"123","author":"Hammers","year":"2013","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.001_bb0315","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/81385","article-title":"Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1","volume":"6","author":"Amagai","year":"2000","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0019-5154.123483","article-title":"Eponymous dermatological signs in bullous dermatoses","volume":"59","author":"Ganapati","year":"2014","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0325","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s40123-023-00725-w","article-title":"Ophthalmic aspects of Stevens-Johnson syndrome and toxic epidermal necrolysis: a narrative review","volume":"12","author":"T\u00f3th","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0330","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2015.05.002","article-title":"Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"160","author":"Sotozono","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0335","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/bjd.17428","article-title":"Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series","volume":"180","author":"Gendreau","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.ajem.2024.04.001_bb0340","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1365-4632.2011.05007.x","article-title":"Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"50","author":"Ang","year":"2011","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijd.IJD_583_17","article-title":"Management of Stevens-Johnson Syndrome-Toxic epidermal necrolysis: looking beyond guidelines!","volume":"63","author":"Kumar","year":"2018","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0355","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J Burn Care Res"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0360","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.ajem.2024.04.001_bb0365","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"34","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.ajem.2024.04.001_bb0370","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0375","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/BCR.0b013e3181cb8cb8","article-title":"What are the fluid requirements in toxic epidermal necrolysis?","volume":"31","author":"Shiga","year":"2010","journal-title":"J Burn Care Res"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0380","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.burns.2016.07.026","article-title":"Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience","volume":"43","author":"McCullough","year":"2017","journal-title":"Burns"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.001_bb0385","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and Meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0390","first-page":"E17","article-title":"Cyclosporine in SJS\/TEN management: a brief review","volume":"97","author":"Shokeen","year":"2016","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.001_bb0395","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0400","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0405","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.001_bb0410","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijd.12423","article-title":"Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies","volume":"54","author":"Barron","year":"2015","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0415","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ajem.2024.04.001_bb0420","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.001_bb0425","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0430","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.burns.2021.11.004","article-title":"Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in toxic epidermal necrolysis, Steven-Johnsons syndrome, and TEN\/SJS overlap - metanalysis and metaregression of observational studies","volume":"48","author":"Krajewski","year":"2022","journal-title":"Burns"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.001_bb0435","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ajem.2024.04.001_bb0440","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319894469","article-title":"Multidisciplinary care in Stevens-Johnson syndrome","volume":"11","author":"Shanbhag","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.001_bb0445","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T10:12:01Z","timestamp":1717495921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675724001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":89,"alternative-id":["S0735675724001542"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2024.04.001","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}